There are 2949 resources available
Prioritising cancer systemic therapies using the ESMO-MCBS: The Israeli experience
Presenter: Raya Leibowitz-Amit
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Slides
Webcast
Shortcomings in study design: Implementation that can skew the ESMO-MCBS results
Presenter: Bishal Gyawali
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Slides
Webcast
Women in science
Presenter: Jocalyn Clark
Session: Women for Oncology Forum: Women in Science
Resources:
Slides
Webcast
ESMO-MCBS: What is new and how are we expanding
Presenter: Nathan Cherny
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Slides
Webcast
Q&A and live discussion, all Speakers online Chairs to moderate Q&A
Presenter: E.G. Elisabeth de Vries
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Webcast
CN34 - Management of immunotherapy toxicities: A new challenge
Presenter: Laura Bascuñana Sanchez
Session: EONS13: Immunotherapy and precision oncology: What do patients need?
Resources:
Abstract
Slides
Webcast
364O - Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
Presenter: Thomas John
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast
LBA11 - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
Presenter: Nadia Harbeck
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
159O - Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
Presenter: Vincent De Jong
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Webcast
160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Presenter: Andreas Schneeweiss
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast